September 22, 2026
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 85% of all lung cancer cases worldwide.1,4 A diagnosis can feel frightening, but it is important to know that treatment options have expanded significantly over the past decade. For many people, modern treatment not only aims to fight the cancer—it is also designed to preserve quality of life.4 This article explains what NSCLC is, how it is diagnosed, and what today’s treatments look like, so you can feel better prepared when speaking with your care team.
What is non-small cell lung cancer, and why is it so important to understand?
NSCLC is a group of cancers that arise from cells within the lungs. In 2022, lung cancer was responsible for an estimated 2.5 million new cases and 1.8 million deaths worldwide—making it the leading cause of cancer-related death globally.1,4 The term “non-small cell” describes how the cancer cells look under a microscope, and it covers three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.4
One important point worth knowing: NSCLC can affect anyone. Up to 25% of all NSCLC cases worldwide occur in people who have never smoked.4 While tobacco smoking remains the most significant risk factor—contributing to 60–70% of cases—other factors also play a role. These include air pollution, occupational exposures such as asbestos, radon gas, and certain genetic factors.1 Understanding this helps remove stigma and encourages everyone to seek care promptly, without hesitation.
How is NSCLC found and diagnosed—and what tests should I expect?
A diagnosis of NSCLC typically begins with recognising symptoms and consulting a doctor. Common symptoms include a cough that does not go away, chest pain, shortness of breath, coughing up blood, unexplained fatigue, and weight loss.1 Because early symptoms can be mild or similar to common respiratory problems, they are sometimes dismissed—which can delay diagnosis.1 If any of these symptoms persist, it is always worth speaking to a healthcare professional.
Once NSCLC is suspected, your care team will carry out a series of tests. These may include imaging scans such as chest X-rays and computed tomography (CT) scans, a bronchoscopy (a procedure to look inside the airways), and a biopsy—a small sample of tissue taken for examination under a microscope.1,4 These tests help determine where the cancer is and whether it has spread. This process is called staging, and it guides the entire treatment plan. NSCLC is classified from stage I (early, localised) to stage IV (advanced, spread to other parts of the body).4
What is biomarker testing—and why is it such a critical step?
Biomarker testing is now a key part of NSCLC care, and it is one of the most important advances in recent years.3 After a biopsy is taken, the tumour tissue is analysed in a laboratory to look for specific genetic changes and proteins. This is called molecular or genomic testing.4
These tests look for specific alterations in the tumour’s genes—such as changes in genes like EGFR, ALK, ROS1, and others—as well as the level of a protein called PD-L1.3 The results help your care team understand the unique “profile” of your cancer. This matters enormously because different molecular profiles respond to different types of treatment. A treatment that is highly effective for one person’s tumour may not work for another’s. In short, biomarker testing helps your care team match the right treatment to your specific cancer—a concept known as personalised or precision medicine.
What are the main treatment options for NSCLC—and how is a plan chosen for me?
Several types of treatment are available for NSCLC, and most people receive a combination of more than one.4 Your care team—made up of specialists from different medical fields working together—will build a plan suited to your situation.
Surgery is the main treatment for early-stage NSCLC, when the tumour is contained within the lung. The goal is to remove the tumour completely. Different surgical approaches exist depending on the size and location of the tumour, and minimally invasive techniques are now widely available, which may lead to faster recovery and less pain.4
Radiotherapy uses high-energy rays to destroy cancer cells. It may be used as the primary treatment when surgery is not possible, or alongside chemotherapy for locally advanced disease.4
Chemotherapy uses medicines that circulate through the bloodstream to kill cancer cells. It is used at various stages—before or after surgery, in combination with radiotherapy, or as part of treatment for advanced disease.4
Immunotherapy is a treatment that helps your own immune system recognise and attack cancer cells more effectively.2 It works by blocking certain proteins that cancer cells use to hide from the immune system. Immunotherapy has become a cornerstone of treatment for many people with NSCLC and may be given alone or combined with chemotherapy, depending on your tumour’s profile.2,3
Targeted therapy consists of medicines designed to act on specific genetic changes found in the tumour. If your biomarker testing identifies an actionable alteration (a genetic change that a specific treatment can directly target), a targeted therapy may be available that is designed to interfere with that change.3,4 These treatments have been associated with improved outcomes for people whose tumours carry certain alterations.3,4
All of these decisions are made together—by specialists in surgery, oncology, radiology, and other fields—in what is called a multidisciplinary team. This team approach is considered essential to getting the best possible outcome.1
How does treatment differ depending on the stage of the cancer?
The stage of NSCLC is one of the most important factors in determining which treatment options may be appropriate.
For early-stage NSCLC (stages I and II), the primary goal is cure. Surgery to remove the tumour is the standard approach when the patient is fit enough to undergo the procedure.1,4 After surgery, additional treatment—such as chemotherapy, immunotherapy, or targeted therapy depending on the tumour’s profile—may be recommended to reduce the risk of the cancer returning.3,4
For stage III (locally advanced) NSCLC, treatment is individualized based on disease and patient characteristics. In fit patients with unresectable disease, concurrent chemotherapy and radiotherapy is the standard approach and may be followed by maintenance immunotherapy. Patients who are not suitable for concurrent chemoradiotherapy because of poor performance status or comorbidities may instead receive sequential chemoradiotherapy or radiotherapy alone.1,4
For advanced or metastatic NSCLC (stage IV, where the cancer has spread to other parts of the body), the primary goal shifts to controlling the disease, relieving symptoms, and maintaining quality of life for as long as possible.1 Systemic treatments—immunotherapy, targeted therapy, and chemotherapy—are the main tools. The choice between them depends heavily on the tumour’s molecular profile and the patient’s overall health.1,3,4
What can I expect in terms of quality of life during and after treatment?
Living with NSCLC and going through treatment brings real challenges, and it is completely normal to have concerns about how treatment will affect your daily life. The good news is that evidence suggests modern treatments, including immunotherapy and targeted therapies, may improve or maintain quality of life compared with chemotherapy alone.4
Different treatments have different side effect profiles. Immunotherapy can sometimes cause the immune system to overreact, affecting organs such as the lungs, intestines, or liver. These side effects can be serious or even life-threatening, so it is important to report any new or worsening symptoms to your care team promptly, as early recognition and treatment can help manage them.2 Targeted therapies can cause skin, nail, or eye changes over time, which may affect quality of life.4
Supportive and palliative care plays an essential role at every stage of NSCLC—not just at the end of life. It includes help with pain management, breathing difficulties, emotional support, and nutritional guidance.1
Do not hesitate to tell your care team about any symptoms or side effects you experience. Reporting symptoms promptly helps your care team manage side effects and make any necessary adjustments to your treatment.2
What progress has been made—and what does the outlook look like for people with NSCLC?
The landscape of NSCLC has changed dramatically over the past decade, and there is genuine reason for measured optimism. Advances in screening, molecular testing, immunotherapy, and targeted therapy have improved survival and quality of life for many patients.3,4
For people at high risk of lung cancer—particularly current or former heavy smokers—low-dose CT (LDCT) screening can detect the disease at earlier, more treatable stages. Studies have shown that LDCT screening is associated with approximately a 20% reduction in lung cancer mortality in high-risk individuals.3,4 If you think you may be eligible for screening, ask your doctor.
Researchers have described the trajectory of NSCLC management as moving towards a disease that can, for more and more people, be managed as a long-term, treatable condition.4 While challenges remain—including overcoming resistance to treatments and improving access to care globally—the direction of progress is encouraging. Clinical trials also offer an important opportunity to access new treatments and contribute to scientific advances.1 Your care team can advise whether any trials may be relevant to your situation.
Conclusion
NSCLC is a serious disease, but treatment has advanced considerably. From personalised biomarker testing to immunotherapy and targeted treatments, your care team has more tools than ever to tailor a plan specifically for you. The most important step is to stay in close contact with your healthcare professionals, ask questions, and report any new symptoms promptly. You do not have to face this alone.
FAQ
1. Is non-small cell lung cancer the same as lung cancer?
NSCLC is the most common type of lung cancer, accounting for approximately 85% of all cases.1 It is different from small cell lung cancer, which is less common but tends to grow more quickly.1 Both are serious conditions, but they are treated differently because of their distinct biology.1
2. Can people who have never smoked get NSCLC?
Yes. Up to 25% of all NSCLC cases worldwide occur in people who have never smoked.4 Other risk factors—including air pollution, occupational exposures, radon, and genetic predisposition—can also increase the risk of NSCLC.1 It is important that people without a smoking history who develop relevant symptoms seek medical advice promptly.
3. What is the purpose of biomarker testing in NSCLC?
Biomarker testing analyses the genetic profile of the tumour to identify specific alterations that may respond to targeted treatments.3 It may also include assessment of biomarkers such as PD-L1 expression as part of the overall evaluation for treatment planning, although the role of PD-L1 and other biomarkers as predictive markers continues to be investigated.3 Biomarker testing is an important component of planning treatment for many patients with NSCLC.
4. What does staging mean, and why does it matter?
Staging describes how far the cancer has spread within the body, from stage I (localised) to stage IV (spread to other organs).4 The stage is one of the most important factors your care team uses to decide which treatments are most appropriate.1 Knowing the stage helps ensure that treatment is neither too limited nor more intensive than necessary.
5. What is immunotherapy and how does it work in NSCLC?
Immunotherapy helps the immune system recognise and destroy cancer cells more effectively by blocking certain proteins that cancer cells use to avoid immune attack.2 In NSCLC, these medicines are called immune checkpoint inhibitors and may be used alone or in combination with chemotherapy, depending on the tumour’s characteristics.2,3 They have become a cornerstone of treatment for many people with NSCLC.3
6. What is targeted therapy, and is it suitable for everyone?
Targeted therapies are medicines designed to act on specific genetic changes found in a tumour.3,4 They are only suitable for people whose tumour carries a specific actionable alteration, which is why biomarker testing is so important.3 Not all NSCLC tumours carry these alterations, and your care team will advise whether targeted therapy is an option for you.4
7. Is surgery always part of NSCLC treatment?
Surgery is the main treatment for early-stage NSCLC when the tumour is localised and the patient is well enough to undergo the procedure.1,4 In cases where surgery is not feasible—due to the location of the tumour or the patient’s overall health—other local treatments such as radiotherapy may be used instead.1 For advanced-stage disease, systemic treatments rather than surgery are typically the main approach.1
8. What is palliative care, and does it mean there is no hope?
Palliative care is not the same as end-of-life care. It is specialised support that helps manage symptoms, pain, and emotional wellbeing at any stage of NSCLC.1 Integrating palliative care early in the treatment process improves quality of life for patients and their families.1 It works alongside cancer treatment, not instead of it.1
9. Can NSCLC be detected early through screening?
NSCLC can be detected at an earlier, more treatable stage through low-dose CT screening in people at high risk—primarily current or former heavy smokers aged 50 to 80.4 Studies have shown that this type of screening is associated with approximately a 20% reduction in lung cancer mortality in eligible individuals.4 If you think you may be eligible, speak to your doctor about whether screening is recommended for you.
10. What should I do if I am experiencing side effects from treatment?
You should report any new or worsening symptoms to your care team as soon as possible.2 For example, immunotherapy can cause specific side effects, so it is important to let your healthcare team know about any changes you experience during treatment.2 Keeping your healthcare team informed is an important part of your care.
This article was written with the assistance of generative AI technology and reviewed for accuracy.
References
